MaxCyte Shares Slide as Investors Weigh $151.8 Million Akron Bio Acquisition
MaxCyte shares fell after its $151.8 million Akron Bio deal, as investors weighed dilution risk, cash use and broader biotech M&A skepticism.
Hegseth Impeachment Vote Puts Pentagon Leadership and Defense Spending in Focus
```json { "title": "Hegseth Impeachment Vote Puts Pentagon Leadership and Defense Spending in Focus", "summary": "A …
Hot CPI Report Sends Yields Higher as Fed Rate-Hike Bets Shake Markets
A hotter October CPI report pushed Treasury yields higher, strengthened the US dollar and forced investors to reassess D…
GFL Environmental Loses Buyout Premium After Board Rejects $52 Offer
GFL Environmental shares plunged after its board rejected a $52 offer and ended a strategic review, removing a near-term…
Informed positions start with informed mornings.
Market-moving analysis and institutional-grade research, complimentary and delivered daily.